down arrow

BioSig Technologies, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US09073N3008
USD
4.62
0.37 (8.71%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

4.374.76

52 Week

0.4014.11
Valuation
Technical
Day's Volume

CASH

620.03 k

Shareholding (Mar 2025)

FII

0.06%

Held by 6 FIIs

DII

97.73%

Held by 3 DIIs

Promoter

0.00%

How big is BioSig Technologies, Inc.?

22-Jun-2025

As of Jun 18, BioSig Technologies, Inc. has a market capitalization of 180.96 million, with recent net sales of 0.02 million and a net profit of -9.72 million. The company's shareholder's funds were -1.44 million, and total assets amounted to 0.84 million.

Market Cap: As of Jun 18, BioSig Technologies, Inc. has a market capitalization of 180.96 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, the company reported net sales of 0.02 million and a net profit of -9.72 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds were -1.44 million, and total assets amounted to 0.84 million.

Read More

What does BioSig Technologies, Inc. do?

22-Jun-2025

BioSig Technologies, Inc. is a medical device company specializing in biomedical signal processing technology for electrophysiology and cardiac procedures. As of March 2025, it has a market cap of $180.96 million and reported a net profit loss of $3 million.

Overview:<BR>BioSig Technologies, Inc. is a commercial-stage medical device company in the Pharmaceuticals & Biotechnology industry, focusing on biomedical signal processing technology for electrophysiology studies and cardiac procedures.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025)<BR>Market cap: USD 180.96 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making)<BR>Industry P/E: NA<BR>Dividend Yield: 0.00%<BR>Debt Equity: -1.35<BR>Return on Equity: -458.82%<BR>Price to Book: 66.78<BR><BR>Contact Details:<BR>Address: 54 WILTON ROAD, 2ND FLOOR, WESTPORT CT : 06880<BR>Tel: 1 203 4095444<BR>Website: https://biosigtech.com/

Read More

Who are in the management team of BioSig Technologies, Inc.?

22-Jun-2025

As of March 2022, the management team of BioSig Technologies, Inc. includes Kenneth Londoner (CEO and Executive Chairman), Jeffrey O'Donnell (Lead Independent Director), Anthony Zook, Andrew Filler, Donald Foley, and Patrick Gallagher (all Independent Directors). They oversee the company's strategic direction and operations.

As of March 2022, the management team of BioSig Technologies, Inc. includes the following individuals:<BR><BR>- Mr. Kenneth Londoner: Executive Chairman of the Board, Chief Executive Officer<BR>- Mr. Jeffrey O'Donnell: Lead Independent Director<BR>- Mr. Anthony Zook: Director<BR>- Mr. Andrew Filler: Independent Director<BR>- Mr. Donald Foley: Independent Director<BR>- Mr. Patrick Gallagher: Independent Director<BR><BR>This team is responsible for guiding the company's strategic direction and overseeing its operations.

Read More

Is BioSig Technologies, Inc. technically bullish or bearish?

20-Sep-2025

As of July 14, 2025, BioSig Technologies, Inc. shows a mildly bullish trend with strong daily moving averages and significant outperformance against the S&P 500, despite mixed signals from Dow Theory and weekly MACD indicators.

As of 14 July 2025, the technical trend for BioSig Technologies, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating bullish momentum, while weekly MACD and KST show mildly bearish signals. Bollinger Bands are bullish across both weekly and monthly time frames. However, the Dow Theory indicates a mixed view with weekly mildly bullish and monthly mildly bearish signals. <BR><BR>In terms of performance, the stock has significantly outperformed the S&P 500 with a year-to-date return of 329.53% compared to the S&P 500's 12.22%, and a one-year return of 1911.95% versus 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 137 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.80

stock-summary
Return on Equity

354.04%

stock-summary
Price to Book

-38.97

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-20 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.91%
0%
-1.91%
6 Months
-28.04%
0%
-28.04%
1 Year
168.6%
0%
168.6%
2 Years
52.73%
0%
52.73%
3 Years
1008.98%
0%
1008.98%
4 Years
-82.43%
0%
-82.43%
5 Years
-0.43%
0%
-0.43%

BioSig Technologies, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is BioSig Technologies, Inc. technically bullish or bearish?

As of 14 July 2025, the technical trend for BioSig Technologies, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating bullish momentum, while weekly MACD and KST show mildly bearish signals. Bollinger Bands are bullish across both weekly and monthly time frames. However, the Dow Theory indicates a mixed view with weekly mildly bullish and monthly mildly bearish signals. In terms of performance, the stock has significantly outperformed the S&P 500 with a year-to-date return of 329.53% compared to the S&P 500's 12.22%, and a one-year return of 1911.95% versus 17.14%....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0.20%
EBIT Growth (5y)
7.13%
EBIT to Interest (avg)
-32.25
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.35
Sales to Capital Employed (avg)
0.02
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
70.43%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
73.83
EV to EBIT
-15.83
EV to EBITDA
-16.00
EV to Capital Employed
-196.40
EV to Sales
196.40
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-458.82%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 5 Schemes (2.21%)

Foreign Institutions

Held by 6 Foreign Institutions (0.06%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -628.57% vs -154.55% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.80",
          "val2": "-3.00",
          "chgp": "-560.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-0.00",
          "val2": "0.20",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-20.40",
          "val2": "-2.80",
          "chgp": "-628.57%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 64.11% vs -5.13% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-12.40",
          "val2": "-28.20",
          "chgp": "56.03%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.30",
          "val2": "-0.20",
          "chgp": "1,250.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.30",
          "val2": "-28.70",
          "chgp": "64.11%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-315,225.00%",
          "val2": "-1,584,000.00%",
          "chgp": "1,26,877.50%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-19.80
-3.00
-560.00%
Interest
0.00
0.00
Exceptional Items
-0.00
0.20
-100.00%
Consolidate Net Profit
-20.40
-2.80
-628.57%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -628.57% vs -154.55% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-12.40
-28.20
56.03%
Interest
0.00
0.00
Exceptional Items
2.30
-0.20
1,250.00%
Consolidate Net Profit
-10.30
-28.70
64.11%
Operating Profit Margin (Excl OI)
-315,225.00%
-1,584,000.00%
1,26,877.50%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs -100.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 64.11% vs -5.13% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About BioSig Technologies, Inc. stock-summary
stock-summary
BioSig Technologies, Inc.
Pharmaceuticals & Biotechnology
BioSig Technologies, Inc. is a commercial-stage medical device company. The Company is commercializing biomedical signal processing technology platform to extract information from physiologic signals. The Company focuses on providing intracardiac signal information to electrophysiologists during electrophysiology (EP) studies and cardiac catheter ablation procedures for atrial fibrillation (AF) and ventricular tachycardia (VT). The Company is engaged in developing the Precise Uninterrupted Real-time evaluation of Electrograms (PURE) electro-pneumatic (EP) System, a surface electrocardiogram and intracardiac multichannel recording and analysis system that acquires, processes and displays electrocardiogram and electrograms required during electrophysiology studies and ablation procedures. The PURE EP System is a signal acquisition and processing technology.
Company Coordinates stock-summary
Company Details
54 WILTON ROAD, 2ND FLOOR , WESTPORT CT : 06880
stock-summary
Tel: 1 203 4095444
stock-summary
https://biosigtech.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."